Henry Schein, Inc. HSIC recently completed the acquisition of substantially all of the assets of Acentus, a national medical ...

Evercore ISI analyst Elizabeth Anderson CFA maintained a Hold rating on Henry Schein (HSIC – Research Report) yesterday and set a price target ...

Tampa, Florida-based Acentus, a national medical supplier, specializes in the delivery of continuous glucose monitors (CGMs).

Fintel reports that on January 6, 2025, B of A Securities upgraded their outlook for Henry Schein (NasdaqGS:HSIC) from ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Shares of Henry Schein, Inc. (NASDAQ:HSIC – Get Free Report) have been assigned an average recommendation of “Moderate Buy” ...

The projected fair value for Henry Schein is US$67.04 based on 2 Stage Free Cash Flow to Equity With US$70.70 share price, Henry Schein appears to be trading close to its estimated fair value ...

Below is Validea's guru fundamental report for HENRY SCHEIN, INC. (HSIC). Of the 22 guru strategies we follow, HSIC rates highest using our Shareholder Yield Investor model based on the published ...

Bank of America upgraded shares of Henry Schein (NASDAQ:HSIC – Free Report) from an underperform rating to a buy rating in a research report sent to investors on Monday, MarketBeat.com reports. Bank ...

As previously reported, BofA analyst Allen Lutz upgraded Henry Schein (HSIC) to Buy from Underperform with a price target of $84, up from $69, ...

Below is Validea's guru fundamental report for HENRY SCHEIN, INC. (HSIC). Of the 22 guru strategies we follow, HSIC rates highest using our Shareholder Yield Investor model based on the published ...

The Acentus transaction follows Henry Schein’s acquisition of Prism Medical Products, LLC in 2021 and Shield Healthcare and ...